Novo Nordisk and Canada-based biotech Aspect Biosystems have expanded their partnership to develop advanced cellular medicines for diabetes, with Aspect acquiring rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk.
Novo’s islet replacement therapy for type 1 diabetes is designed to restore blood glucose control without the need for chronic immune suppression. The therapy is allogeneic, enabling scalable manufacturing using off-the-shelf cells.
The deal, which builds on work that began in 2023, involves integrating select Novo Nordisk cell therapy research, development, and manufacturing capabilities and expertise into Aspect’s platform. Aspect’s full-stack tissue therapeutic platform integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering and advanced biomaterials.
Per the agreement, Aspect will lead development, manufacturing and commercialization, with Novo Nordisk eligible to receive royalties and milestone payments on future product sales from Aspect.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!